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ABSTRACT  25 
A design of experiments (DOE) approach (2-level full factorial design) was used to 
investigate the effect of several formulation and process variables on the properties of fast 
disintegrating tablets comprising starch-based pellets and excipient granules and to optimize and 
validate the design space. The percentage of starch pellets (30-50% w/w), type of disintegrants 
(Ac-di-sol, Explotab, Polyplasdone), percentage of external disintegrant (4-8% w/w) and 30 
compression force (5-15 kN) were the evaluated factors (24 runs + 9 centre points = 33 
experiments), while tablet hardness, friability and disintegration time were the studied tablet 
properties (responses). 
Starch pellets were prepared by extrusion-spheronisation. Excipient granules containing 
microcrystalline cellulose, lactose, internal disintegrant (8%) and polyvinylpyrrolidone K-30 35 
(4%) were prepared by wet granulation. Pellets, granules (700-1000 µm) and external 
disintegrant were mixed and compressed into oblong tablets (17.1 mm long, 8.2 mm wide). 
Evaluation of the effects calculated from the DOE results showed that a lower concentration 
of starch pellets and higher compression force were required to yield tablets with a high hardness, 
a low friability (<1%) and short disintegration time (<3 min). Polyplasdone granules had the 40 
lowest porosity and friability which was reflected in the DOE study, where the Polyplasdone-
containing tablets were harder, less friable and disintegrated faster compared to Ac-di-sol and 
Explotab-containing tablets. Monte carlo simulations at the optimal factor settings (30% starch 
pellets, 4% Polyplasdone and 10 kN compression force) indicated that a robust system was 
formed as the probability to exceed the limits was low for all responses. Validation of the design 45 
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space (at optimal settings) showed that the results predicted via the DOE models correlated well 
with the observed experimental data. 
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1. INTRODUCTION 
Multiparticulates have several therapeutic and technological advantages over single-unit 
dosage forms. Being small (<2 mm), pellets or multiparticulates can distribute evenly in the 65 
gastrointestinal tract, resulting in fewer adverse effects. Pellets also reduce the risk of dose 
dumping compared to single unit dosage forms and result in a reproducible bioavailability 
(Bodmeier, 1997; Celik, 1994). Pellets can be either filled into capsules or compressed into 
tablets called multiple unit pellet systems (MUPS), which rapidly disintegrate into smaller units. 
Compared to capsules, MUPS have a lower production cost (Beckert et al., 1998; Bodmeier, 70 
1997; Nicklasson et al., 1999) and they can contain a higher drug load, leading to improved 
patient compliance (Bechard and Leroux, 1992). MUPS are also tamper proof and can be divided 
into smaller units (Abdul et al., 2010; Beckert et al., 1998).  
Microcrystalline cellulose (MCC) has been the gold standard for preparing pellets by 
extrusion-spheronisation. However, MCC pellets show lack of disintegration and 75 
incompatibilities, since drug decomposition as well as drug adsorption onto the MCC fibres have 
been reported (Dukic-Ott et al., 2009). As a result, researchers have been evaluating other 
excipients as pelletisation aid, which may substitute MCC for extrusion-spheronisation purposes. 
A resistant and crystalline high-amylose starch grade (VELOXTM 
The purpose of this study was to examine the feasibility to compress these starch-based 
pellets into fast disintegrating multiparticulate tablets (MUPS), by examining the effect of 
MCS) has been reported to be 
among the promising alternatives for MCC. The starch-based pellets were of high quality 80 
(process yield, roundness, surface structure) and had a fast disintegration and drug release 
(Dukic-Ott et al., 2008; Dukic et al., 2007). 
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several formulation (starch pellet percentage, type and concentration of external disintegrant) and 85 
process (compression force) parameters on the resulting tablet properties (hardness, friability and 
disintegration time), using a design of experiments (DOE) approach. DOE was also used to 
optimize the tablet formulation and to determine and evaluate the design space. 
 
  90 
6 
 
2. MATERIALS 
2.1. Starch pellets 
Starch-based pellets (710-1000 µm) were prepared by extrusion-spheronisation, using a high 
amylose, crystalline and resistant starch grade (VELOX™ MCS, Henkel Corporation, New 
Jersey, USA) as main excipient (83.2%). Hydroxy propyl methyl cellulose (HPMC) (Methocel® 95 
E15 LV, Colorcon, Dartford, UK) (4.8%) was used as binder in the pellets and sorbitol 
(Sorbidex®
2.2. Excipient granules 100 
 P16615, Cerestar, Vilvoorde, Belgium) (10%) was added as a plasticizer, to modify 
the wet mass consistency. Demineralised water was used as granulation liquid. Riboflavin 
sodium phosphate (2%) (Sigma Aldrich, France) was used as model drug. 
Microcrystalline cellulose (54.5%) (MCC, Avicel PH 101, FMC Biopolymers, Ireland) and α-
lactose monohydrate (33.5%) (Pharmatose® 200M, DMV, Veghel, Nederland) were used as 
fillers for granulation. Polyvinylpyrrolidone (4%) (PVP, Kollidon® 30, BASF, Ludwigshafen, 
Germany) was used as binder and crosslinked croscarmellose sodium (Ac-di-sol®, IMCD 
Limited, Sutton), sodium starch glycolate (Explotab®, JRS Pharma, Rosenberg, Germany) or 105 
crospovidone (Polyplasdone® XL, ISP, Germany) were incorporated in the granules as internal 
disintegrant (8%). Demineralised water (89% w/w of dry mass) was used as granulation liquid. 
To prepare the multiparticulate tablets, the pellets and granules were mixed with an external 
disintegrant, colloidal silicium dioxide (1%) (Aerosil®, Alpha Pharma, Belgium) and sodium 
stearyl fumerate (0.5%) (Lubrisanaq®
  
, Pharmatrans Sanaq, Basel, Switzerland).  110 
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3. METHODS 
3.1. Preparation of starch pellets 
Pellets were produced by extrusion-spheronisation according to Dukic et al. (Dukic et al., 
2007). Dry mixing was performed in a tumbling mixer (Turbula® 
3.2. Wet granulation for preparation of excipient granules 
model T2A, W.A. Bachofen, 115 
Basel, Switzerland) for 15 min. This powder mixture was granulated with demineralised water 
for 10 min in a planetary mixer (Kenwood Chief, Hampshire, UK), using a K-shaped mixing arm. 
Water was added during the first 30 s of the wet granulation phase. To ensure uniform mixing, 
material adhering to the mixing bowl was removed regularly. The obtained wet mass was 
extruded at an extrusion speed of 50 rpm using a single screw extruder (Dome extruder DG-L1, 120 
Fuji Paudal, Tokyo, Japan) equipped with a dome-shaped extrusion screen with 1.0 mm 
perforations. The resulting extrudates were spheronized for 3 min at a speed of 1000 rpm using a 
spheroniser having a friction plate with cross-hatched geometry (Caleva Model 15, Caleva, 
Sturminster Newton, Dorset, UK). The pellets were dried overnight in an oven at 40 °C. Finally 
the pellets of size fraction 710-1000 µm were separated using a sieve shaker (Retsch, Haan, 125 
Germany).  
Wet granulation was carried out to prepare placebo granules (containing lactose and MCC) 
with a particle size matching the size of the pellets. MCC (54.5%), lactose (33.5%) and 
disintegrant (8%) (either Ac-di-sol, Explotab or Polyplasdone) were mixed in a tumbling mixer 130 
for 15 min. Wet granulation was performed by adding an aqueous solution containing 4% PVP 
as binder to the powder mixture. After mixing for 15 min in a planetary mixer, the wet mass was 
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passed through a 1480 µm sieve and the obtained granules were dried in an oven at 40 °C for 24 
h. The final product was sieved to isolate the 710-1000 µm size fraction. 
3.3. Characterization of pellets and granules 135 
3.3.1. Image analysis 
The size and shape of the pellets were determined using an image analysis system. 
Photomicrographs of the pellets were taken with a digital camera (Camedia® C-3030 Zoom, 
Olympus, Tokyo, Japan), linked with a stereomicroscope (SZX9 DF PL 1.5x, Olympus, Tokyo, 
Japan). A cold light source (Highlight 2100, Olympus, Germany) and a ring light guide (LG-R66, 140 
Olympus, Germany) were used to obtain top light illumination of the pellets against a dark 
surface. The images were analyzed by image analysis software (AnalySIS®
3.3.2. Friability 150 
, Soft Imaging 
System, Munster, Germany). The magnification was set in a way that one pixel corresponded to 
5.7 µm and around 300 pellets were analyzed from every batch. Each individual pellet was 
characterized by its mean Feret diameter (FD) (average of 180 calliper measurements with an 145 
angle of rotation of 1°), and the overall average FD value of all pellets analyzed in a batch was 
calculated (average FD). Each individual pellet was also characterized by the aspect ratio (AR: 
ratio of longest Feret diameter and its longest perpendicular diameter) and two-dimensional 
shape factor (eR) (Dukic et al., 2007). 
The friability was determined (n=3) using a friabilator (PTFE, Pharmatest, Hainburg, 
Germany). Pellets and granules (Iwt=10 g) were placed in an abrasion wheel together with 200 
glass beads (diameter: 4 mm) and the sample was subjected to falling shocks for 10 min at a 
rotational speed of 25 rpm. Afterwards the fines were removed by sieving through a 250 µm 
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mesh for 5 min (2 mm amplitude). The fraction above 250 µm (Fwt
Friability (%) = [(I
) was used to calculate the 155 
friability of pellets according to the following equation (Eq. 1): 
wt - Fwt)/ Iwt
 3.3.3. Bulk and tapped density 
] x 100                                                                                 Eq (1) 
The bulk (ρb) and tapped density (ρt) of pellets and granules were determined using a tapping 
machine (J. Englesman, Ludwigshafen, Germany) (n=3). A 100 ml measuring cylinder was filled 160 
with the sample up to the mark. The volumes at the beginning (bulk volume, V0) and after 1000 
taps (tapped volume, V1000) were recorded. The bulk density was calculated as the ratio of mass 
and initial volume V0, while the tapped density was calculated as the ratio of mass and tapped 
volume V1000
Carr's Index = (ρ
. The compressibility index (C%) and Hausner ratio (HR) were calculated 
according to the following equations (Eq. 2, 3) : 165 
t - ρb/ ρt
Hausner Ratio (HR) = ρ
)*100                                                                                                    Eq (2) 
t/ρb
3.3.4. Porosity 
                                                                                                          Eq (3) 
The porosity (ε) of the dried granules and pellets (710-1000 µm) was calculated using the 
following equation (Eq. 4): 170 
Ε = 100 (1 - ρa/ρh
Where ρ
)                                                                                                                          Eq (4) 
h is the true density (determined by helium pycnometry, Accupyc 1330 Micromeritics, 
Norcross, USA) and ρa is the apparent (granular) density (calculated from the envelope volume 
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as determined by mercury porosimetry,
3.4. Preparation of multiparticulate tablets 
 Autopore III, Micromeritics, Norcross, Georgia, USA) 
(n=3).  175 
 The composition of the multiparticulate tablets is given in Table 1. Pellets, granules (710-
1000 µm), external disintegrant, silicium dioxide and sodium stearyl fumerate were mixed in a 
tumbling mixer for 1 h. From this mixture oblong tablets (length 17.1 mm, width 8.2 mm, weight 
800 mg) were manufactured on a single punch tablet press (Korsch EK0, Berlin, Germany) at a 180 
production rate of 1000 tablets per hour.  
3.5. Design of Experiments 
The influence of several formulation and process parameters on the properties of the 
multiparticulate tablets was studied using Design of Experiments (DOE). The effects of three 
formulation variables (percentage of starch pellets, type of disintegrant, percentage of external 185 
disintegrant) and one process variable (compression force) were studied by applying a 2-level 
full factorial design. The experimental space within which the factors were studied, are detailed 
in Table 2. The disintegrant type was a qualitative factor. Design centre point experiments 
combining each type of disintegrant and the centre points of the other factors (40% starch pellets, 
6% each disintegrant, 10 kN compression force) were performed, resulting in 3 centre point 190 
experiments. Each centre point experiment was performed in triplicate. Hence, in total 2^3 * 3 + 
9 = 33 experiments were performed (Table 3). All experiments were performed in a randomized 
order. Tablet hardness, friability and disintegration time were included as response variables. 
The results were analyzed using Modde software (Version 9.0, Umetrics, Umea, Sweden).  
 195 
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3.6. Tablet characterization 
Tablet hardness was determined from the force required to fracture the tablets along their 
longest axis using a tablet hardness tester (PTB 311 Pharma Test, Hainburg, Germany) (n=6).  
The tablet friability was determined in a friabilator (PTFE Pharma Test, Hainburg, Germany), 
described in the European Pharmacopoeia, at a speed of 25 rpm for 4 min. The percentage 200 
weight loss was expressed as the tablet friability. 
The disintegration time was determined (n=6) using the apparatus described in the European 
Pharmacopoeia (PTZ-E Pharma Test, Hainburg, Germany) (Eur. Pharm. 2009). These tests were 
performed in distilled water at 37.0 ± 0.5 °C using disks.  
Scanning Electron Microscopy (SEM) was used to visualize the surface morphology of the 205 
tablets, pellets and granules. Samples were coated with platinum by means of a sputter coater 
(Auto Fine Coater, JFC-1300, Jeol, Tokyo, Japan) to assure conductivity. Photomicrographs 
were taken with a scanning electron microscope (Jeol JSM 5600 LV, Jeol, Tokyo, Japan). Digital 
microscope (KH 7700, Hirox, Japan) was used for visual inspection (qualitative study) of the 
effect of the compaction process on pellet integrity.  210 
The content uniformity of selected formulation was determined by crushing 10 tablets and 
dissolving the powder in 100 ml of distilled water. After filtration through a 0.2 µm cellulose 
acetate filter (Sartorius, Gottingen, Germany), the riboflavin content was determined via UV-
analysis (Perkin-Elmer UV/VIS λ12, Norwalk, CT, USA) at 445 nm.  
Drug release from selected formulations was performed according to the USP paddle method 215 
(VK 8000, Vankel, New Jersey, USA) at a rotational speed of 100 rpm and at a temperature of 
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37.0 ± 0.5°C. Demineralised water (900 ml) was used as dissolution medium. Samples of 5 ml 
were withdrawn from the dissolution vessel at different time intervals. The samples were 
analyzed using double-beam spectrophotometer (Perkin-Elmer UV/VISs λ12, Norwalk, CT, 
USA) at a wavelength of 445 nm. Each batch was analyzed in triplicate. 220 
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4. RESULTS AND DISCUSSION 
4.1. Development of MUPS tablets 
As the first step of the development of multiparticulate tablets, starch pellets were mixed with 225 
0.5% sodium stearyl fumerate as preliminary experiments with magnesium stearate resulted in a 
too low tablet hardness. After compression at 25 kN the resulting compacts were easy to de-
aggregate and the original pellets could be retrieved by gently shaking the tablet in a petri dish. 
Although the pellets deformed (Figure 1) there was not sufficient binding between the pellets to 
produce a coherent tablet. When only die wall lubrication (with 1% sodium stearyl fumerate 230 
suspension in ethanol) was used, the binding properties did not improve although there was a 
higher tendency of the pellets to fragment. These results were confirmed via image analysis: the 
mean aspect ratio increased from 1.1 to 1.3 and 1.4 after lubrication with 0.5% sodium stearyl 
fumerate and in-die lubrication, respectively, while the average feret diameter decreased from 
1.30 to 1.18 and 0.90 mm.   235 
It was essential to use suitable inert compression diluents to improve the compactibility of 
starch-based pellets. These diluents should have minimal segregation propensity, cushion the 
pellets during compression, have a high dilution potential, disintegrate rapidly to release the 
starch-based pellets and have minimal effect on the drug release kinetics.        
The effect of excipients on compression of multiparticulates has been the subject of many 240 
publications, the excipients varying from powders to placebo beads/granules. Lundqvist et al. 
evaluated the effect of diluents on tablet properties using a mixture of drug pellets 
(MCC/lactose/drug, ratio: 50/48/2), cushioning pellets (barium sulphate/MCC/glyceryl 
monostearate, ratio: 50/20/30) and disintegrating pellets (MCC/disintegrant, ratio: 50:50) 
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(Lundqvist et al., 1997). Beckert et al. compressed coated MCC pellets into disintegrating tablets 245 
using powders and granules of various excipients along with disintegrants (Beckert et al., 1996, 
1998). Ghanam et al. formulated MUPS tablets by embedding κ-carrageenan pellets in a 
silicified microcrystalline cellulose powder (SMCC HD 90) (Ghanam et al., 2010). Habib et al. 
developed placebo beads containing different MCC/lactose ratios and different levels of super 
disintegrants by extrusion–spheronization, followed by freeze drying and examined the effects of 250 
these variables on water requirement, porosity, compactibility, compressibility and disintegration 
of MUPS tablets. High levels of MCC and different superdisintegrants, especially croscarmellose 
sodium, increased the granulation liquid requirement, thus producing freeze-dried beads with 
higher porosity and compactibility (Habib et al., 2002).  
As starch-based pellets with a narrow size distribution were used, excipient granules of 255 
similar size and shape were considered as the best choice, as compression diluents in order to 
minimize the risk of segregation during compression and in order to ensure content uniformity of 
the drug incorporated into the pellets (Beckert et al., 1998; Ivic et al., 2009). These placebo 
granules should deform/fragment during compaction with pellets, in order to fill the voids 
between the pellets and also to surround them so that the tablet is held together by excipient-260 
excipient interactions. Ideally these placebo granules should fracture into progeny primary 
powder particles thus facilitating maximum tablet bonding (Aulton et al., 1994). 
Similar to Habib et al., this study used granules consisting of MCC and lactose as 
compression aids; however these granules were prepared via wet granulation and oven drying. 
Combining these granules with starch-based pellets yielded tablets with an acceptable hardness 265 
and low friability, but a long disintegration time. To enhance the disintegration, an internal 
disintegrant phase was added to the placebo granules, either Polyplasdone, Explotab or Ac-di-sol 
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were combined with MCC and lactose. These granules in combination with starch pellets and an 
extragranular disintegrant phase yielded acceptable multiparticulate tablets (Figure 2). The 
deformation of the starch-based pellets was limited as tablet cohesion was due to the deformation 270 
of the MCC/lactose granules (Figure 3). 
The Carr’s index and Hausner ratio indicated that the different granule formulations had a 
good flowability. The friability of Polyplasdone granules was less than 1%, while the Ac-di-sol 
and Explotab-based granules were more friable (Table 4). 
4.2. Experimental design  275 
From the experimental results (Table 3), the effects of all studied variables and the variable 
interactions were graphically and statistically interpreted for all responses. Figure 4 show the 
effect plots for hardness, disintegration time and friability, where negative values indicate a 
negative effect of a specific variable on the response factor. In these plots the effects are sorted 
from largest to smallest, and. Replicate plots (data not shown) were used to evaluate per response 280 
whether the variability of repeated experiments was smaller than the overall variability. Next, 
normal distribution of the experimental results per response (hardness, disintegration time and 
friability) was evaluated using the histogram plots. In case of disintegration time and friability, 
logarithmic transformation was needed to obtain a normal distribution of the experimental results. 
This transformation improved the model fit for these responses. Based on the DOE experimental 285 
results, models describing the factors/response relationship were calculated for each response. 
Model refinement was done by excluding the non-significant model terms, hence improving the 
model predictability.   
4.2.1. Hardness 
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Increasing the compression force significantly increased the hardness, yielding stronger 290 
tablets (Figure 4A). A high percentage of starch pellets resulted in reduced bonding forces within 
the tablets, confirmed by a lower hardness. Polyplasdone had a positive effect on hardness, 
irrespective of the concentration used in external phase. In contrast, Explotab as disintegrant in 
the granules reduced the hardness significantly and Ac-di-sol had a negligible effect. These 
results are similar to the results obtained by Habib et al. (Habib et al., 2002), where Polyplasdone 295 
as external phase during compression of MCC pellets yielded stronger tablets compared to 
formulations with Ac-di-sol and Explotab as external disintegrant. The disintegrant concentration 
had a limited effect on hardness. Kornblum et al. demonstrated that Polyplasdone acted both as 
binder and disintegrant in tablets made by wet granulation (Vankamp et al., 1983). This was 
confirmed in the current study, as granules containing Polyplasdone had a low porosity and 300 
friability compared to Explotab and Ac-di-sol granules (Table 4). Furthermore, this was also 
reflected in the DOE as Polyplasdone-containing tablets were harder and less friable, probably 
due to the binding properties of Polyplasdone acting as an adhesive. The interaction effect 
between percentage of starch pellets and Ac-di-sol or Explotab increased the hardness whereas 
the use of Polyplasdone decreased the hardness. 305 
4.2.2. Disintegration time 
In the present study, the disintegrant was incorporated in both the intra (8%) - and extra-
granular (4-8%) phase. Increasing the compression force significantly increased the 
disintegration time of MUPS tablets (Figure 4B). Mainly the compression force affected the 
disintegration time, whereas the other factors had a limited effect. As all tablets disintegrated 310 
very rapidly (within 5 min), the multiparticulate behaviour of the compressed system could be 
maintained in all formulations. Increasing the percentage of starch pellets significantly reduced 
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the disintegration time. Polyplasdone lowered the disintegration time, whereas the other two 
disintegrants did not have a significant effect on tablet disintegration. Polyplasdone has a porous 
particle morphology which enables it to rapidly absorb liquids into the tablet by capillary action 315 
and generate rapid volume expansion and hydrostatic pressure, which induce tablet disintegration, 
without forming a gel at higher concentrations (Polyplasdone®
 The effect plot for disintegration time suggested an increase at higher compression force, 320 
whereas the interaction of Polyplasdone as disintegrant with a higher compression force 
prolonged disintegration time. This might be related to tablet hardness, as Polyplasdone 
improved binding within the tablets.  
 Superdisintegrants). On the other 
hand, Ac-di-sol and Explotab show a disintegration effect mainly via swelling (Gorman et al., 
1982).  
4.2.3. Friability 
Friability of the tablets compressed at lower compression force and having a higher 325 
percentage of starch pellets was significantly higher (Figure 4C). Mainly Polyplasdone-
containing tablets had a low friability, whereas the friability of tablets formulated with Ac-di-sol 
and Explotab increased. These results are correlated with the granule friability (Table 4) as 
Polyplasdone granules were less friable compared to agglomerates prepared with Ac-di-sol and 
Explotab, due to the increased binding properties of Polyplasdone. During friability testing some 330 
tablet formulations disintegrated into the individual pellets. This was related to the amount of 
external disintegrant in the tablet, which significantly increased the friability. 
4.3. Process optimization 
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To optimize the final tablet formulation and process conditions, the required limits of the 
response values were clearly defined, and the combinations of variables which resulted in tablets 335 
meeting the required specifications were calculated using the Modde optimizer software to 
obtain tablets with the following properties: a hardness between 80 and maximum 200 N, a 
friability below 1% and a disintegration time below 3 min. The sweet spot plots (Figure 5) show 
those regions where the combinations of variables resulted in tablets having the required 
specifications (green area). These response criteria are mainly met when Polyplasdone  is used as 340 
external disintegrant, irrespective of the concentration used. Ac-di-sol containing formulations 
still meet the criteria at higher compression force, whereas Explotab offered limited 
opportunities to meet the requirements. It is obvious that the obtained design space is more 
robust when Polyplasdone is used as disintegrant, compared to Ac-di-sol and Explotab. Strict 
control of these optimum settings is clearly needed to result in a high hardness, low friability and 345 
short disintegration time.  
Sweet spot plots are limited by the number of dimensions and the lack of probability 
estimation in the predicted surface (i.e. design space). Therefore, the values of the response 
factors (hardness, disintegration time, friability) were predicted via Monte Carlo simulations 
(using Modde software) by randomly varying the settings around their optimum value (but 350 
within the lower and upper limits). The resulting distribution of each response factor (presented 
as a histogram) allows to determine the probability that the accepted limit of a response factor is 
exceeded when the settings fluctuate around their optimum. Monte Carlo simulations at the 
optimum factor settings (4% crospovidone, 10 kN compression force and 30% starch pellets) 
showed that there is a 0% probability for hardness and disintegration time and a 0.1% probability 355 
for friability to exceed the specification limit values (Figure 6). At the above-mentioned 
19 
 
optimum settings validation of the design space outlined via the DOE was performed, and the 
results predicted based on the DOE model correlated well with the observed experimental data 
(Table 5).  
4. 4. Content uniformity and drug release 360 
When processing the optimized tablet formulation (contained 30% starch pellets and 4% 
Polyplasdone in the external phase and is compressed at 10 kN) in automatic mode (i.e. filling 
the pellets into the tablet die from a feed hopper by gravity), the weight variation and content 
uniformity were within the acceptable limits, confirming the absence of segregation between 
granules and pellets. The entire riboflavin content was released within 15 min from pellets and 365 
MUPS tablets, confirming the suitability of starch-based pellets to formulate fast-disintegrating 
MUPS. 
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5. CONCLUSION 
The compression of starch-based pellets as such was not possible. However, the addition of 370 
excipients granules (formulated with MCC, lactose and a disintegrant) yielded fast disintegrating 
MUPS tablets. Via DOE, it was determined that selection of the proper formulation (disintegrant 
type, concentration of starch pellets, concentration of external disintegrant) and process 
(compression force) parameters was of paramount importance to obtain MUPS tablets with 
optimum hardness, friability and disintegration time. 375 
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  Table 1. Composition of the multiparticulate tablets 
 
 
 440 
 
 
 
 
 445 
 
 
 
 
 450 
 
 
 
 
 455 
Ingredient Concentration (% w/w) 
Starch pellets Variable 
Disintegrant Variable 
Silicium dioxide 1 
Sodium stearyl fumerate 0.5 
Excipient granules q.s. ad 100 % 
25 
 
Table 2. DOE factors with their experimental space 
 
Variables Units 
Levels  
- + 
Starch pellets % w/w 30 50 
Concentration of external disintegrant  % w/w 4 8 
Compression force  kN 5 15 
External disintegrant type 
 
 
Ac-di-sol, Explotab,  
Polyplasdone 
 
 
 460 
 
 
 
 
 465 
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Table 3. 2-level full factorial design with 4 variables: A. type of disintegrant (at 3 levels); B. 
compression force (kN); C. percentage of starch pellets (%); D. percentage of external 470 
disintegrant (%). The quantitative variables A, B and C were evaluated at 2 levels. 3 replicates of 
the central point for each type of disintegrant were performed. The experiments were performed 
in randomized order. 
 
Exp. No. 
Variables Hardness 
(N) 
Disintegration 
time (sec) 
Friability 
(%) B C D 
Variable A:  Ac-di-sol 
1 5 30 4 34.9 37 9.2 
2 15 30 4 156.6 125 0.12 
3 5 50 4 10.0 38 19.2  
4 15 50 4 107.6 162 2.1 
13 5 30 8 31.4 56 24.5 
14 15 30 8 133.7 178 0.9 
15 5 50 8 18.9 59 22.9 
16 15 50 8 68.7 79 4.5 
25 10 40 6 54.9 55 4.7 
26 10 40 6 73.7 55 4.7 
27 10 40 6 75.3 65 5.8 
Variable A: Explotab 
5 5 30 4 36.7 21 6 
6 15 30 4 114.7 314 0.4 
7 5 50 4 12.0 22 15.4 
8 15 50 4 70.7 151 2.4 
17 5 30 8 42.3 25 12.6 
27 
 
18 15 30 8 113.6 240 1.2 
19 5 50 8 7.9 23 20.8 
20 15 50 8 49.3 184 5.1 
28 10 40 6 81.0 98 6.7 
29 10 40 6 66.1 108 6.2 
30 10 40 6 53.0 91 4.5 
Variable A: Polyplasdone 
9 5 30 4 59.3 16 3.1 
10 15 30 4 214.7 224 0.1 
11 5 50 4 20.4 16 10.2 
12 15 50 4 84.1 159 1.2 
21 5 30 8 64.0 15 8.9 
22 15 30 8 203.6 275 0.1 
23 5 50 8 7.5 15 17.5 
24 15 50 8 80.9 * 1.6 
31 10 40 6 91.2 90 0.9 
32 10 40 6 88.1 66 1.3 
33 10 40 6 83.2 63 1.6 
 
* Outlier 475 
 
 
 
 
 480 
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Table 4. Characterisation of placebo granules formulated with MCC (54. 5%), lactose (33.5%), 
disintegrant (8%) and PVP (4%) 
 
 485 
 
 
 
 
 490 
 
 
 
 
 495 
 
 
 
 
Evaluation 
parameters Granules with different disintegrants 
 Ac-di-sol Explotab Polyplasdone 
Carr’s index (%) 13.0 14.2 14.9 
Hausner ratio 1.15 1.17 1.18 
Porosity (%) 65.8 60.8 52.1 
Friability (%) 12.9 12.2 0.2 
29 
 
Table 5. Process validation of the DOE model: predicted response values via DOE model vs. 500 
observed response values. The following settings of the different factors were defined: 
compression force 10 kN, starch pellets concentration: 30%, external disintegrant concentration: 
4%, disintegrant type: Polyplasdone 
Response Predicted Observed 
 
Hardness (N) 
 
153 
 
143 
Friability (%) 0.41 0.39 
Disintegration time (sec) 90 81 
 
 505 
 
 
 
 
 510 
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Figure 1. SEM pictures of starch based pellets 
 
                       515 
                  (a)                                      (b)                                              (c) 
 
 
 
 520 
 
 
 
 
 525 
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Figure 2. Appearance of multiparticulate tablets 530 
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 540 
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Figure 3. SEM and optical microscopy pictures of the fracture plane of multiparticulate tablets  
 550 
 
                                                    (a)                                         (b) 
 
 
 555 
 
 
 
 
 560 
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Figure 4. Effect plots 565 
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Figure 5. Sweet spot plots 570 
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Figure 6. Monte carlo simulations 
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FIGURE LEGEND 
Figure 1:  
SEM pictures of starch-based pellets before (a) and after compression using die lubrication (b) 590 
and 0.5% sodium stearylfumerate as lubricant (c). 
Figure 2:  
Appearance of multiparticulate tablets containing 30% starch pellets and 64.5% MCC/lactose 
granules. Riboflavin (2%) was added as a marker to the starch-based pellets, resulting in yellow-
colored pellets. 595 
Figure 3:  
SEM (a) and optical microscopy (b) pictures of the fracture plane of multiparticulate tablets 
formulated with starch-based pellets (30%) and MCC/lactose (64.5%) granules 
Figure 4:  
Effect plots for hardness (A), disintegration time (B) and friability (C). Studied factors:  600 
compression force (CF), disintegrant type (DT), percentage of starch pellets (SP), percentage of 
disintegrant (D). 
Figure 5: 
 Sweet spot plot highlighting the combination of factors (green areas) resulting in tablets having 
the required properties (i.e., hardness: 80 - 200N, disintegration time: <180 sec, friability <1%). 605 
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Dark blue and light blue area represents combinations of factors resulting in 2 and 1 responses 
within the desired ranges, respectively. The white area represents combinations where none of 
the responses met the specifications. 
Figure 6:  
Predicted response profiles for the response variables. The yellow line represents the target value 610 
for the responses here. The red lines are the specification limits for each response residual. The 
green region represents the probability of a prediction when the optimum process settings are 
used. 
 
